Orgenesis

ORGS49

Penny Stock

$2.11arrow_drop_down34.37%-$1.11

Penny Stock

ORGS49

$2.11

arrow_drop_down34.37%-$1.11

Penny Stock

Performance History

Key Stats
Open	$1.95
Prev. Close	$3.23
EPS	-24.46
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$5.63M
PE Ratio	-

	LOW	HIGH
Day Range	1.57	2.36
52 Week Range	2.50	10.80

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-24.46

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Orgenesis (ORGS)

Orgenesis Inc (ticker symbol ORGS) is a biotech company engaged in the development and commercialization of advanced cell therapies. The company focuses on the treatment of various diseases such as diabetes, liver diseases, and cancer. ORGS has a rich history in the field of cell therapy, with a strong track record of innovation and scientific excellence.

The stock price history of Orgenesis Inc is characterized by fluctuations and volatility. Over the years, the stock has shown both upward and downward trends, reflecting the market dynamics and investor sentiment. Investors interested in ORGS should closely monitor the stock's price movements and consider various factors before making any investment decisions.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Ms. Vered Caplan M.Sc.
Headquarters: Germantown
Employees: 167
Exchange: NASDAQ

Keep an eye on Orgenesis

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Orgenesis 's (ORGS) price per share?

The current price per share for Orgenesis (ORGS) is $2.11. The stock has seen a price change of -$1.11 recently, indicating a -34.37% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Orgenesis (ORGS)?

For Orgenesis (ORGS), the 52-week high is $10.8, which is 411.85% from the current price. The 52-week low is $2.5, the current price is -15.6% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Orgenesis (ORGS) a growth stock?

Orgenesis (ORGS) has shown an average price growth of -7.23% over the past three years. It has received a score of 90 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Orgenesis as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Orgenesis (ORGS) stock price performance year to date (YTD)?

As of the latest data, Orgenesis (ORGS) has a year-to-date price change of -57.11%. Over the past month, the stock has experienced a price change of 37.91%. Over the last three months, the change has been -75.43%. Over the past six months, the figure is -61.66%. Looking at a longer horizon, the five-year price change stands at -93.53%.

help

Is Orgenesis (ORGS) a profitable company?

Orgenesis (ORGS) has a net income of -$64.92M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$53.64M. Furthermore, the EBITDA is $0.

help

What is the market capitalization of Orgenesis (ORGS)?

Orgenesis (ORGS) has a market capitalization of $5.63M. The average daily trading volume is 2.11, indicating the stock's liquidity and investor engagement.

News

EARNINGS RELEASES AND OPERATING RESULTS

Apr 15, 2024

Orgenesis Provides Year End Business Update

PARTNERSHIPS

Apr 10, 2024

Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility

Why Stryve Foods Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

CHANGES IN COMPANY'S OWN SHARES

Mar 4, 2024

Orgenesis Inc. Announces $2.3 Million Private Placement